Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a comprehensive meta-analysis across 147 randomized trials clarifies which lipid-lowering therapies reduce lipoprotein(a); an updated meta-analysis comparing valve-in-valve TAVI versus redo surgical aortic valve replacement shows better short-term survival but trade-offs in hemodynamics; and a large multi-society imaging study demonstrates noninvasive pressure–volume loops and intraventricular pressure gradients from 3D echocardiography with re
Summary
Three impactful cardiology studies stood out today: a comprehensive meta-analysis across 147 randomized trials clarifies which lipid-lowering therapies reduce lipoprotein(a); an updated meta-analysis comparing valve-in-valve TAVI versus redo surgical aortic valve replacement shows better short-term survival but trade-offs in hemodynamics; and a large multi-society imaging study demonstrates noninvasive pressure–volume loops and intraventricular pressure gradients from 3D echocardiography with reference values.
Research Themes
- Therapeutic modulation of lipoprotein(a)
- Structural heart interventions: valve-in-valve TAVI vs redo surgery
- Noninvasive cardiac mechanics and hemodynamics via 3D echocardiography
Selected Articles
1. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
Across 147 randomized trials (145,314 participants), PCSK9 monoclonal antibodies, inclisiran, CETP inhibitors, and niacin significantly reduced Lp(a), whereas statins, bempedoic acid, ezetimibe, omega-3s, and fibrates did not. Greater absolute reductions occurred with higher baseline Lp(a).
Impact: This meta-analysis provides the most comprehensive comparative evidence to date on pharmacologic Lp(a) lowering, directly informing therapy selection for patients with elevated Lp(a).
Clinical Implications: For patients with elevated Lp(a), consider PCSK9 mAbs or inclisiran as first-line Lp(a)-lowering strategies, with CETP inhibitors and niacin as alternatives where appropriate. Statins should not be expected to lower Lp(a) and may require adjunctive therapies.
Key Findings
- PCSK9 monoclonal antibodies reduced Lp(a) by ~6.37 mg/dL (≈29% from baseline).
- Inclisiran reduced Lp(a) by ~4.76 mg/dL (≈22% from baseline).
- CETP inhibitors and niacin reduced Lp(a) by ≈46% and ≈37% from baseline, respectively.
- Statins, bempedoic acid, ezetimibe, omega-3 fatty acids, and fibrates had no significant effect on Lp(a).
- Higher baseline Lp(a) was associated with larger absolute reductions for PCSK9 mAbs, inclisiran, and CETP inhibitors.
Methodological Strengths
- Large-scale meta-analysis of 147 RCTs with 145,314 participants following PRISMA guidelines
- Drug class–specific effect estimates with subgroup analysis by baseline Lp(a)
Limitations
- Heterogeneity in Lp(a) assays and trial designs across included RCTs
- Clinical outcome effects of Lp(a) lowering were not directly assessed
Future Directions: Prospective trials should test whether pharmacologic Lp(a) lowering translates to reduced ASCVD events and define thresholds for treatment initiation.
BACKGROUND AND AIMS: Lipoprotein (a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease. In this study we aimed at assessing the effect of currently available lipid-lowering therapies (LLTs) on Lp(a) plasma levels. METHODS: A meta-analysis was performed according to the PRISMA guidelines. Databases were searched up to May 2025. Inclusion criteria were: (1) randomized controlled trials (RCTs) in adults (≥18 years), phase II, III or IV; (2) English language; (3) comparing the effect of lipid-lowering drugs vs placebo (addition of the same drug to both intervention and control group was acceptable); (4) reporting the effects on Lp(a) levels; (5) intervention duration of more than 3 weeks. The between-group (treatment-placebo) Lp(a) absolute mean differences and 95% confidence intervals were calculated for each drug class separately. RESULTS: A total of 145,314 subjects from 147 RCTs were included. Statins, bempedoic acid, ezetimibe, omega-3 fatty acids, and fibrates did not affect Lp(a) concentration. Lp(a) levels were significantly reduced by PCSK9 monoclonal antibodies (PCSK9mAbs, -6.37 mg/dL [-7.26 to -5.47], a 29% reduction from baseline), inclisiran (-4.76 mg/dL [-5.83 to -3.69], a 22% reduction from baseline), CETP inhibitors (CETPi, -6.77 mg/dL [-8.67 to -4.88], a 46% reduction from baseline), and niacin (-7.06 mg/dL [-9.27 to -4.85], a 37% reduction from baseline). In the subgroup analysis by baseline Lp(a) levels, a larger absolute reduction of Lp(a) levels was observed with increasing baseline levels of Lp(a) for PCSK9mAbs, inclisiran, and CETPi. CONCLUSIONS: Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels. Further research is necessary to understand whether this effect would translate into a clinically relevant cardiovascular benefit.
2. Valve in valve transcatheter versus redo surgical replacement of a failing surgical bioprosthetic aortic valve: An updated systematic review and meta-analysis.
Pooling 26 studies (n=17,581), valve-in-valve TAVI showed lower 30-day and 1-year mortality and less major bleeding than redo surgical AVR. However, ViV-TAVI had higher transprosthetic gradients, more severe patient–prosthesis mismatch, and more paravalvular leak.
Impact: This updated synthesis informs procedural choice in failed surgical bioprostheses, balancing survival benefits of ViV-TAVI against hemodynamic compromises that may affect long-term outcomes.
Clinical Implications: In suitable anatomy, ViV-TAVI is favored for lower early mortality and bleeding. Pre-procedural planning should mitigate high gradients and PVL (e.g., valve sizing, commissural alignment, bioprosthetic ring fracture strategies) and anticipate PPM risk.
Key Findings
- ViV-TAVI reduced 30-day mortality (RR 0.55) and 1-year mortality (RR 0.85) versus redo-SAVR.
- Major bleeding at 30 days was lower with ViV-TAVI (RR 0.58).
- ViV-TAVI had higher transprosthetic gradients and increased severe patient–prosthesis mismatch (RR 1.64) and paravalvular leak (RR 2.44).
- No significant differences in 30-day stroke or myocardial infarction.
Methodological Strengths
- Comprehensive PRISMA-guided meta-analysis with large pooled sample and random-effects modeling
- Evaluation of both clinical and echocardiographic endpoints
Limitations
- Predominantly observational studies with potential selection bias and residual confounding
- Device generations and surgical techniques vary across studies
Future Directions: Prospective comparative registries and trials should examine long-term durability, hemodynamics, and quality of life; techniques to mitigate PPM and PVL in ViV-TAVI warrant further evaluation.
BACKGROUND: With the aging population, degeneration of surgical aortic valves is an important clinical scenario. Currently, in most European countries, both redo surgery [redo-surgical aortic valve replacement (SAVR)] and valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) are established alternatives for treating such patients. This meta-analysis aims to compare redo-SAVR and ViV-TAVI for treating a failing bioprosthetic aortic valve. METHODS: A systematic search was performed from inception to June 2023. After selecting all appropriate trials according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a random effect meta-analysis was performed. Clinical and echocardiographic outcomes were compared among the groups. RESULTS: Twenty-six studies with a total of population of 17,581 patients were included [ViV-TAVI (n = 9163) or redo-SAVR (n = 8418]. ViV-TAVI was associated with lower 30-day mortality (RR: 0.55; 95%CI: 0,47 to 0,66) and 1-year mortality (RR: 0.85; 95%CI: 0.75 to 0.96), major bleeding events (RR: 0.58; 95%CI: 0.42-0.79), and a trend towards lower new pacemaker implantations (RR: 0.70; 95%CI: 0.49-1.01) at 30 days. On the other hand, ViV-TAVI resulted in a higher mean transprosthetic gradient and higher rates of severe patient-prosthesis mismatch (RR: 1.64; 95%CI: 1.01 to 2.65) and paravalvular leak (RR: 2.44; 95%CI: 1.73-3.45) as compared to redo-SAVR. No significant difference was observed in 30-day myocardial infarction (RR: 0.90; 95%CI: 0.56 to 1.46) or stroke (RR: 0.77; 95%CI:0.55 to 1.06). CONCLUSION: ViV-TAVI has a satisfying safety profile with better short-term survival outcomes as compared to redo-SAVR. However, adequate pre-procedural planning of VIV-TAVI cases is needed, in order to minimize the risk of a suboptimal hemodynamic outcomes following ViV-TAVI.
3. Noninvasive assessment of left ventricular performance using pressure-volume loops, blood propulsion and strain tensors: results from the World Alliance of Societies of Echocardiography study.
Using physics-based analysis of 3D echocardiography in 1,403 normal subjects, investigators generated noninvasive LV pressure–volume loops, intraventricular pressure gradients, and strain tensors, and provided normative values by sex, age, and race. IVPG declined with aging but showed minimal sex differences.
Impact: Introduces validated, physics-based, noninvasive surrogates of PV loops and IVPG with normative datasets, potentially transforming hemodynamic assessment beyond invasive catheterization.
Clinical Implications: These tools may enhance comprehensive functional assessment in echo labs, supporting earlier detection of subtle dysfunction and facilitating longitudinal monitoring without invasive procedures.
Key Findings
- Physics-based methods derived noninvasive LV pressure–volume loops, IVPG, and 3D strain tensors from 3DE.
- In 1,403 normal subjects, IVPG decreased with aging and showed minimal sex-related variation.
- Asian participants had smaller LV size but higher EF, strain, and PV loop scores compared with Whites; IVPG was broadly similar across races.
- Feasibility of the advanced 3DE analysis was approximately 70%.
Methodological Strengths
- Large, international normal cohort with standardized 3DE acquisition
- Physics-grounded modeling enabling comprehensive mechanical and hemodynamic assessment
Limitations
- Cross-sectional study in normal subjects; clinical predictive value in disease states not established
- Feasibility at ~70% may limit universal applicability and depends on image quality
Future Directions: Validate these noninvasive metrics against invasive gold standards in diverse cardiac diseases and assess prognostic utility and responsiveness to therapy.
AIMS: Left ventricular (LV) pressure-volume (PV) loops, LV strain tensors, and intraventricular pressure gradients (IVPG) provide physiological information on cardiovascular performance and the interaction between LV and arterial system. Given that acquisition of PV loops and IVPG require invasive measurements, there is interest in the development of new noninvasive tools. This work aims to (i) demonstrate the application of noninvasive methods based on three-dimensional echocardiography (3DE) for describing PV loops and haemodynamic performance in terms of IVPG, in conjunction to LV strain tensors and (ii) to determine sex-, age-, and race-related normative values. METHODS AND RESULTS: This work is based on 3DE data from the World Alliance of Societies of Echocardiography study (1403 normal subjects). It applies physics-based techniques to construct noninvasive PV loops, assess blood propulsion using IVPG and 3D deformation using LV strain tensors. Sex- and age-related differences in strain and PV loop are limited to some parameters only, while haemodynamic performance in terms of IVPG does not vary with sex and is reduced with aging. Asian populations are characterized by smaller hearts, higher EF, strain, and PV loop scores than Whites, which in turn have similar LV size to Blacks and higher EF, strain, and PV loop scores, while IVPG was more similar across the populations. CONCLUSION: This study analysed a large normal population with physics-based methods that allow a deep mechanical and haemodynamic analysis of 3DE with 70% feasibility and provided reference values for a series of advanced parameters and their dependency on sex, age, and race.